Home›Stock Screener›Rossari Biotech›Financial Statements

Rossari Biotech Complete Financial Statements

8 Years of Data
2026 - 2019

In FY2026, Rossari Biotech (ROSSARI) reported revenue ₹704 Cr, net profit ₹46 Cr and EPS ₹8.30, with a net profit margin of 6.5% and ROE of 3.5%. Full financial statements from FY2019 to FY2026 (8 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review ROSSARI price earnings ratio to evaluate earnings-based valuation against sector peers.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 6.53% 2026 data
EBITDA Margin 13.78% 2026 data
Operating Margin 11.00% 2026 data
Return on Assets 2.01% 2026 data
Return on Equity 3.45% 2026 data

Balance Sheet Ratios

Current Ratio 7.49 2026 data
Equity Ratio 58.24% 2026 data
Asset Turnover 0.31 2026 data

ROSSARI Revenue, Net Profit & EBITDA — Year-on-Year Growth

ROSSARI YoY (Mar 2025 vs Mar 2026) — revenue +21.0%, net profit +35.3%, EBITDA +36.6%, expenses +19.2%. For live price, earnings ratios and company overview, see Rossari Biotech share price chart.

Revenue Growth
+21.0%
Year-over-Year
Net Profit Growth
+35.3%
Year-over-Year
EBITDA Growth
+36.6%
Year-over-Year
Expense Growth
+19.2%
Year-over-Year
Assets Growth
+20.7%
Year-over-Year
Equity Growth
+12.5%
Year-over-Year
Operating Cash Flow Growth
+218.6%
Year-over-Year
Investing Cash Flow Growth
-76.0%
Year-over-Year
Financing Cash Flow Growth
+306.3%
Year-over-Year

ROSSARI Income Statement — Revenue, EBITDA & Net Profit

Rossari Biotech revenue ₹704 Cr, EBITDA ₹97 Cr, net profit ₹46 Cr, EPS ₹8.30 (2026) — net profit margin 6.5%. Explore Rossari Biotech intrinsic worth to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars Mar 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Mar 2024 Jun 2024 Dec 2024 Sept 2023 Mar 2023 Jun 2023 Dec 2023 Sept 2022 Mar 2022 Jun 2022 Dec 2022 Sept 2021 Mar 2021 Jun 2021 Dec 2021 Sept 2020 Mar 2020 Jun 2020 Dec 2020 Sept 2019 Jun 2019 Dec 2019
Revenue 704 588 582 545 583 499 473 491 514 485 410 413 467 426 442 436 390 387 220 234 434 176 162 112 211 151 129 163
Expenses 608 514 510 476 513 432 409 425 448 420 352 353 400 369 387 377 335 339 182 194 381 142 136 86 176 122 106 133
EBITDA 97 74 71 70 70 67 64 66 66 65 58 60 67 58 56 59 55 48 38 40 53 34 26 26 35 29 23 30
Operating Profit Margin % 11.00% 12.00% 12.00% 12.00% 12.00% 13.00% 13.00% 13.00% 13.00% 13.00% 13.00% 14.00% 14.00% 13.00% 12.00% 13.00% 14.00% 12.00% 17.00% 16.00% 11.00% 18.00% 15.00% 22.00% 16.00% 19.00% 17.00% 18.00%
Depreciation 24 18 18 18 20 15 16 15 18 15 16 14 15 16 17 15 16 10 7 6 16 6 5 4 6 4 4 4
Interest 9 6 6 6 8 4 3 4 5 5 4 6 4 8 5 5 5 2 1 1 5 1 1 1 0 1 1 1
Profit Before Tax 64 50 48 46 43 48 46 47 42 45 37 40 48 34 34 39 35 36 30 33 33 28 20 21 28 24 19 25
Tax 18 13 13 13 10 13 11 12 11 12 8 10 13 10 10 10 9 10 8 9 10 7 5 5 7 6 5 6
Net Profit 46 37 34 34 33 35 34 35 32 33 29 29 34 24 24 29 26 26 22 25 23 21 15 16 22 18 14 18
Earnings Per Share (₹) 8.30 6.66 6.22 6.07 5.92 6.39 6.18 6.32 5.73 5.97 5.25 5.30 6.23 4.34 4.37 5.21 4.66 4.77 4.32 4.52 4.09 4.07 3.11 3.19 4.16 3.66 2.93 3.77

ROSSARI Balance Sheet — Assets, Liabilities & Shareholders' Equity

ROSSARI total assets ₹2,289 Cr, total equity ₹1,333 Cr, total liabilities ₹ Cr (2026) — ROE 3.5%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019
ASSETS
Total Assets 2,289 1,896 1,572 1,368 1,257 561 472 250
Current Assets 1,244 1,042 844 720 609 355 326 160
Fixed Assets 866 598 578 585 607 181 94 74
Capital Work in Progress 173 140 47 16 1 0 22 3
Investments 405 84 63 51 36 0 18 0
Other Assets 0 1,074 885 715 612 380 338 173
LIABILITIES
Total Liabilities
Current Liabilities 166 174 100 104 157 2 36 4
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 1,333 1,185 1,048 915 805 409 287 124
Share Capital 11 11 11 11 11 10 10 4
Reserves & Surplus 1,322 1,174 1,037 904 794 398 277 119

ROSSARI Cash Flow Statement — Operating, Investing & Financing

Rossari Biotech operating cash flow ₹137 Cr, investing ₹-183 Cr, financing ₹65 Cr, net cash flow ₹19 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019
Operating Activities 137 43 152 29 48 57 71
Investing Activities -183 -104 -181 -299 -37 -190 -37
Financing Activities 65 16 61 292 -25 157 -29
Net Cash Flow 19 -44 32 22 -14 24 5